Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
Neuro Oncol. 2021 Oct 1;23(10):1634-1646. doi: 10.1093/neuonc/noab138.
Pediatric low-grade gliomas (pLGGs) are the most common brain tumor in children and are associated with lifelong clinical morbidity. Relative to their high-grade adult counterparts or other malignant childhood brain tumors, there is a paucity of authenticated preclinical models for these pLGGs and an incomplete understanding of their molecular and cellular pathogenesis. While large-scale genomic profiling efforts have identified the majority of pathogenic driver mutations, which converge on the MAPK/ERK signaling pathway, it is now appreciated that these events may not be sufficient by themselves for gliomagenesis and clinical progression. In light of the recent World Health Organization reclassification of pLGGs, and pilocytic astrocytoma (PA), in particular, we review our current understanding of these pediatric brain tumors, provide a conceptual framework for future mechanistic studies, and outline the challenges and pressing needs for the pLGG clinical and research communities.
小儿低度恶性胶质瘤(pLGGs)是儿童中最常见的脑肿瘤,与终生临床发病率相关。与成人高级别肿瘤或其他恶性儿童脑肿瘤相比,这些 pLGGs 的经证实的临床前模型很少,对其分子和细胞发病机制的了解也不完整。尽管大规模的基因组分析已确定了大多数致病性驱动突变,这些突变集中在 MAPK/ERK 信号通路,但现在人们认识到,这些事件本身可能不足以导致神经胶质瘤的发生和临床进展。鉴于最近世界卫生组织对 pLGGs 的重新分类,特别是对毛细胞型星形细胞瘤(PA)的重新分类,我们回顾了对这些小儿脑肿瘤的现有认识,为未来的机制研究提供了一个概念框架,并概述了 pLGG 临床和研究界的挑战和紧迫需求。